Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 17Terminated 14Active not recruiting 9Recruiting 8Withdrawn 4Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Carcinoma 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × poly ICLC × Clear all
NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Washington University School of Medicine

Phase 1 Not yet recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡